India defends generics amid 'vested interests' sullying claims
This article was originally published in Scrip
Executive Summary
India's ministry of commerce and industry has swung into damage control mode following an avalanche of media reports that indirectly questioned the quality of Indian medicines against the backdrop of Ranbaxy's settlement of an investigation by the US Department of Justice (DOJ) concerning data integrity and manufacturing processes at two of its domestic sites.